| Outcome Measures: |
Primary: Part 1: Area Under the Curve (AUC) of Glucose Infusion Rate (GIR) From 0-6 Hours, 0-6 hours|Part 2: Time to Reduction in Plasma Glucose by 80 Milligrams Per Deciliter (mg/dL) Following CSII Bolus, Time to reduction is reported as the maximum time it took for any participant receiving each treatment sequence to achieve a reduction in plasma glucose by 80 mg/dL. During the course of the study, it became difficult to establish a stable hyperglycemic plateau with a target glucose level of 220 mg/dL, even after adjusting several operational parameters. The study was stopped early, prior to enrolling the planned 24 participants for Part 2. Thus, analysis for this endpoint was not conducted. Raw data (as a maximum) are reported., 0-10 hours|Part 3: Time to Achieve Plasma Glucose >90 mg/dL After Release of Hypoglycemic CSII Clamp, 0-12 hours | Secondary: Part 1: Time-action Profile, Assessed by GIR in Euglycemic Participants, up to approximately 10 hours|Part 1: Mean Maximum Concentration (Cmax), up to approximately 22 hours|Part 1: Time to Achieve Maximum Concentration (Tmax), up to approximately 22 hours|Part 1: Early Time to 50% Maximum Serum Insulin Concentration (t50%) Max, up to approximately 22 hours|Part 1: Time to 50% of Total AUC (AUC0-last), up to approximately 22 hours|Part 1: Fractional and Absolute AUC0-1hr, 0 to 1 hour|Part 1: Fractional and Absolute AUC2hr-end, 2 to approximately 22 hours|Part 1: Area Under the Curve From Time Zero to the Last Measureable Concentration (AUC0-last), up to approximately 22 hours|Part 1: Mean Residence Time (MRT), up to approximately 22 hours|Part 2: Plasma Glucose Concentration Over Time, Plasma glucose concentration over time is reported as the maximum concentration for any participant receiving each treatment sequence. During the course of the study, it became difficult to establish a stable hyperglycemic plateau with a target glucose level of 220 mg/dL, even after adjusting several operational parameters. The study was stopped early, prior to enrolling the planned 24 participants for Part 2. Thus, analysis for this endpoint was not conducted. Raw data (as a maximum) are reported., up to approximately 10 hours|Part 2: Insulin Analog Serum Concentration as a Function of Time Following Bolus Insulin Infusion, Insulin analog serum concentration is reported as the maximum concentration for any participant receiving each treatment sequence. During the course of the study, it became difficult to establish a stable hyperglycemic plateau with a target glucose level of 220 mg/dL, even after adjusting several operational parameters. The study was stopped early, prior to enrolling the planned 24 participants for Part 2. Thus, analysis for this endpoint was not conducted. Raw data (as a maximum) are reported., up to approximately 10 hours|Part 3: Plasma Glucose Concentration Over Time, up to approximately 12 hours|Part 3: Insulin Analog Serum Concentration as a Function of Time Following Termination of Insulin Infusion, up to approximately 12 hours
|
